Subcutaneous Tecentriq Hybreza will provide patients and physicians increased flexibility for administration of the immunotherapy across approved indications for Tecentriq, including non–small cell lung cancer, small cell lung cancer, and hepatocellular carcinoma.
Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a...
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies...
Click the title above for a link to open the Pharmaceutical Executive February 2025 issue in an interactive PDF format.
Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes.
The TileDB CEO discusses how the life sciences can overcome these limitations.
James Foster, CEO and co-founder of Virax Biolabs, discusses how the industry is preparing for potential regulatory changes to vaccine...
